Case Overview

In a pharmaceutical patent dispute resolved in under 100 days, Bayer AG, Bayer Pharma AG, and Janssen Pharmaceuticals, Inc. secured a dismissal with prejudice against Indian generic manufacturer Umedica Laboratories Pvt., Ltd. over alleged infringement of patents covering XARELTO® (rivaroxaban) — one of the world’s best-selling anticoagulants. Filed December 21, 2023, in the Delaware District Court before Chief Judge Richard G. Andrews, Case No. 1:23-cv-01456 concluded on March 27, 2024, with both parties stipulating to mutual dismissal and bearing their own costs.

The case centered on two U.S. patents protecting rivaroxaban formulations and Umedica’s proposed generic tablets at 2.5 mg, 10 mg, 15 mg, and 20 mg dosage strengths. For patent attorneys tracking pharmaceutical patent litigation trends and IP professionals monitoring ANDA-related disputes, this case offers instructive insights into litigation strategy, settlement dynamics, and the competitive pressures shaping the branded drug versus generic manufacturer battleground.

The Parties

Patents at Issue

This case involved two U.S. patents protecting rivaroxaban formulations. These patents sit within the pharmaceutical formulation space, protecting not merely the active compound but the specific dosage forms and manufacturing innovations that differentiate XARELTO® commercially.

• • U.S. Patent No. 9,539,218 B2 — covering pharmaceutical compositions and formulations of rivaroxaban
• • U.S. Patent No. 10,828,310 B2 — covering additional formulation and/or dosage-related innovations for rivaroxaban-based products

The Verdict & Legal Analysis

Outcome

On March 27, 2024, the parties filed a joint stipulation of dismissal pursuant to Federal Rules of Civil Procedure Rules 41(a)(1) and 41(c). The stipulation dismissed all claims and defenses asserted by both plaintiffs and defendant with prejudice — meaning neither party may relitigate the same claims in future proceedings. Critically, the agreement specified that all parties shall bear their own costs, disbursements, and attorneys’ fees, indicating no financial damages or fee-shifting award was part of the resolution.

No injunctive relief, royalty award, or declared invalidity finding was entered — the case concluded entirely through mutual stipulation without judicial determination on the merits.

Key Legal Issues

The case was classified as an infringement action, the standard Hatch-Waxman litigation trigger initiated when a generic manufacturer files an ANDA with a Paragraph IV certification challenging branded drug patents. Under this framework, the branded company’s filing of suit within 45 days of notice automatically triggers a 30-month regulatory stay, preventing FDA approval of the generic during litigation — giving branded manufacturers significant leverage to negotiate or litigate from a position of strength.

The absence of any disclosed merits ruling makes it impossible to assess the relative strength of validity or infringement positions. However, the rapid dismissal with prejudice — and the mutual cost-bearing provision — suggests a negotiated resolution, most likely a settlement agreement or licensing arrangement whose terms were not disclosed in public court filings. This structure is common in pharmaceutical patent disputes, where branded companies may grant authorized generic licenses or market entry dates in exchange for dismissal.